

# Gerald F Watts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8270935/publications.pdf>

Version: 2024-02-01

738  
papers

42,921  
citations

2544

96  
h-index

3732

179  
g-index

755  
all docs

755  
docs citations

755  
times ranked

28996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
2	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	2.2	2,132
3	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	2.2	1,392
4	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	2.2	993
5	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	2.2	835
6	Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). <i>Lancet</i> , The, 1992, 339, 563-569.	13.7	818
7	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
8	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	2.2	644
9	Learning by doing “An exploration of experience, critical incidents and reflection in entrepreneurial learning. <i>International Journal of Entrepreneurial Behaviour and Research</i> , 2000, 6, 104-124.	3.8	566
10	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>European Heart Journal</i> , 2016, 37, 1944-1958.	2.2	542
11	The Agenda for Familial Hypercholesterolemia. <i>Circulation</i> , 2015, 132, 2167-2192.	1.6	539
12	Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3956-3964.	3.6	523
13	Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 1085-1094.	4.7	513
14	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 655-666.	11.4	473
15	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2541-2548.	2.8	465
16	Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. <i>Lancet</i> , The, 1992, 340, 1430-1432.	13.7	459
17	Statin Toxicity. <i>Circulation Research</i> , 2019, 124, 328-350.	4.5	439
18	Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Vascular Reactivity of the Forearm Microcirculation in Hyperlipidemic, Overweight Men. <i>Circulation</i> , 2000, 102, 1264-1269.	1.6	331

#	ARTICLE	IF	CITATIONS
19	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 850-861.	11.4	329
20	Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. <i>European Heart Journal</i> , 2016, 37, 1384-1394.	2.2	326
21	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	1.7	316
22	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1742-1759.	1.6	301
23	Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension,. <i>American Journal of Clinical Nutrition</i> , 2002, 76, 1007-1015.	4.7	296
24	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	1.5	289
25	Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 135, 2133-2144.	1.6	270
26	Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. <i>American Journal of Clinical Nutrition</i> , 1999, 70, 817-825.	4.7	253
27	Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1519-1523.	3.4	237
28	Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. <i>European Journal of Clinical Nutrition</i> , 2002, 56, 1137-1142.	2.9	225
29	Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. <i>Clinical Science</i> , 2008, 114, 611-624.	4.3	225
30	Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1278-1285.	2.8	221
31	The Role of Nutraceuticals in Statin Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	2.8	216
32	Metabolic Risk Factors for Vascular Disease in Obstructive Sleep Apnea. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 190-195.	5.6	212
33	Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome. <i>Diabetes</i> , 2003, 52, 803-811.	0.6	207
34	Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. <i>Journal of Human Hypertension</i> , 2007, 21, 297-306.	2.2	206
35	Waist circumference, waist-to-hip ratio and body mass index as predictors of adipose tissue compartments in men. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 441-447.	0.5	198
36	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3140-3148.	3.6	198

#	ARTICLE	IF	CITATIONS
37	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 280-290.	11.4	191
38	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189
39	Familial hypercholesterolaemia: A model of care for Australasia. <i>Atherosclerosis Supplements</i> , 2011, 12, 221-263.	1.2	181
40	Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. <i>Diabetologia</i> , 2002, 45, 420-426.	6.3	180
41	Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. <i>Atherosclerosis</i> , 2003, 166, 85-93.	0.8	172
42	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	6.1	169
43	Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 753-761.	2.3	166
44	Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. <i>American Journal of Clinical Nutrition</i> , 2003, 77, 300-307.	4.7	165
45	Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3842-3848.	3.6	164
46	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
47	Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia. <i>Diabetes</i> , 2002, 51, 2377-2386.	0.6	162
48	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	2.8	162
49	New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 493-503.	1.8	150
50	Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2014, 8, 390-400.	1.5	149
51	Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1461-1467.	3.4	148
52	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.8	148
53	Personal model-assisted identification of NAD <sup>+</sup> and $\gamma$ -glutathione metabolism as intervention target in NAFLD. <i>Molecular Systems Biology</i> , 2017, 13, 916.	7.2	147
54	Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet. <i>Diabetes Care</i> , 2010, 33, 1134-1139.	8.6	145

#	ARTICLE	IF	CITATIONS
55	Statin therapy and plasma coenzyme Q10 concentrationsâ€”A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	7.1	145
56	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpointsâ€”A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2016, 62, 930-946.	3.2	145
57	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891.	1.6	144
58	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet</i> , The, 2021, 398, 1713-1725.	13.7	142
59	The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. <i>Clinical Endocrinology</i> , 1994, 41, 345-350.	2.4	140
60	Endothelium-dependent and independent vasodilation studied at normoglycaemia in Type I diabetes mellitus with and without microalbuminuria. <i>Diabetologia</i> , 2001, 44, 593-601.	6.3	139
61	The impact of statin therapy on plasma levels of von Willebrand factor antigen. <i>Thrombosis and Haemostasis</i> , 2016, 115, 520-532.	3.4	138
62	Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives. <i>Atherosclerosis</i> , 2006, 185, 227-239.	0.8	137
63	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.8	137
64	New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2013, 35, 1082-1098.	2.5	134
65	New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 559-567.	2.6	133
66	Fibrates, dyslipoproteinaemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 1999, 10, 561-574.	2.7	129
67	Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 1041-1046.	3.4	129
68	Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity. <i>Clinical Chemistry</i> , 2002, 48, 877-883.	3.2	129
69	Recent advances in pharmacotherapy for hypertriglyceridemia. <i>Progress in Lipid Research</i> , 2014, 56, 47-66.	11.6	128
70	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). <i>Nature Medicine</i> , 2022, 28, 96-103.	30.7	128
71	Association between statin use and plasma D-dimer levels. <i>Thrombosis and Haemostasis</i> , 2015, 114, 546-557.	3.4	127
72	Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. <i>International Immunology</i> , 2003, 15, 915-925.	4.0	126

#	ARTICLE	IF	CITATIONS
73	Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 565-574.	2.8	126
74	Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA - Journal of the American Medical Association, 2022, 327, 1679.	7.4	126
75	Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes, Obesity and Metabolism, 2005, 7, 406-413.	4.4	125
76	Assessment of central and peripheral arterial stiffness Studies indicating the need to use a combination of techniques. American Journal of Hypertension, 2005, 18, 249-260.	2.0	123
77	Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia, 1995, 38, 959-967.	6.3	119
78	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry and Laboratory Medicine, 2020, 58, 496-517.	2.3	119
79	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). American Journal of Cardiology, 2017, 119, 40-46.	1.6	116
80	Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. European Heart Journal, 2018, 39, 2577-2585.	2.2	116
81	Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opinion on Pharmacotherapy, 2009, 10, 2973-2985.	1.8	114
82	Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. International Journal of Obesity, 1998, 22, 414-423.	3.4	112
83	Markers of Triglyceride-rich Lipoprotein Remnant Metabolism in Visceral Obesity. Clinical Chemistry, 2002, 48, 278-283.	3.2	109
84	Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Human Reproduction, 2008, 23, 2352-2358.	0.9	109
85	Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells. Nature Immunology, 2013, 14, 90-99.	14.5	106
86	Regular ingestion of black tea improves brachial artery vasodilator function. Clinical Science, 2002, 102, 195-201.	4.3	105
87	Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 537-548.	0.5	105
88	Adipocytokines and VLDL Metabolism: Independent Regulatory Effects of Adiponectin, Insulin Resistance, and Fat Compartments on VLDL Apolipoprotein B-100 Kinetics?. Diabetes, 2005, 54, 795-802.	0.6	105
89	Toward an international consensus Integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of Clinical Lipidology, 2017, 11, 858-871.e3.	1.5	105
90	Coenzyme Q10 Improves Endothelial Dysfunction in Statin-Treated Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 810-812.	8.6	104

#	ARTICLE	IF	CITATIONS
91	Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment. Review of Diabetic Studies, 2013, 10, 133-156.	1.3	104
92	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
93	Dietary fatty acids and progression of coronary artery disease in men. American Journal of Clinical Nutrition, 1996, 64, 202-209.	4.7	103
94	Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis, 1998, 141, 17-30.	0.8	102
95	Effect of Dietary Fatty Acids on Human Lipoprotein Metabolism: A Comprehensive Update. Nutrients, 2015, 7, 4416-4425.	4.1	101
96	Value of Measuring Lipoprotein(a) DuringÂCascade Testing for FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2019, 73, 1029-1039.	2.8	99
97	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	1.5	98
98	Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: A study in familial lipoprotein-lipase deficiency. Atherosclerosis, 1992, 95, 119-125.	0.8	96
99	Urinary albumin excretion in healthy adult subjects: Reference values and some factors affecting their interpretation. Clinica Chimica Acta, 1988, 172, 191-198.	1.1	95
100	Dyslipidemia in Visceral Obesity. American Journal of Cardiovascular Drugs, 2004, 4, 227-246.	2.2	94
101	Adiponectin and other Adipocytokines as Predictors of Markers of Triglyceride-Rich Lipoprotein Metabolism. Clinical Chemistry, 2005, 51, 578-585.	3.2	93
102	Regular ingestion of black tea improves brachial artery vasodilator function. Clinical Science, 2002, 102, 195.	4.3	92
103	Demystifying the management of hypertriglyceridaemia. Nature Reviews Cardiology, 2013, 10, 648-661.	13.7	92
104	Factorial study of the effect of nâ€“3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. American Journal of Clinical Nutrition, 2006, 84, 37-43.	4.7	91
105	Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E626-E632.	3.5	90
106	Identification of Lipoproteins of Intestinal Origin in Human Atherosclerotic Plaque. Clinical Chemistry and Laboratory Medicine, 2003, 41, 792-5.	2.3	90
107	Effect of Weight Loss on LDL and HDL Kinetics in the Metabolic Syndrome. Diabetes Care, 2007, 30, 2945-2950.	8.6	90
108	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90



#	ARTICLE	IF	CITATIONS
109	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	7.1	90
110	High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. <i>PLoS Biology</i> , 2020, 18, e3000870.	5.6	89
111	The effects of $\omega$ 3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. <i>Journal of Hypertension</i> , 2009, 27, 1863-1872.	0.5	87
112	Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. <i>Heart</i> , 2011, 97, 350-356.	2.9	87
113	Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 260-271.	1.5	87
114	Preserved Endothelial Function in Patients With Severe Hypertriglyceridemia and Low Functional Lipoprotein Lipase Activity. <i>Journal of the American College of Cardiology</i> , 1997, 29, 964-968.	2.8	86
115	Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. <i>Atherosclerosis</i> , 2003, 168, 169-179.	0.8	85
116	Introducing the "Drucebo"™ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	7.3	84
117	Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. <i>European Journal of Clinical Investigation</i> , 2002, 32, 429-436.	3.4	82
118	Familial hypercholesterolemia in China: Prevalence and evidence of underdetection and undertreatment in a community population. <i>International Journal of Cardiology</i> , 2014, 174, 834-836.	1.7	82
119	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <i>Nature Reviews Cardiology</i> , 2020, 17, 360-377.	13.7	82
120	Nutrient intake and progression of coronary artery disease. <i>American Journal of Cardiology</i> , 1994, 73, 328-332.	1.6	80
121	Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. <i>Circulation</i> , 2017, 135, 338-351.	1.6	80
122	Sex differences in endothelial function in normal and hypercholesterolaemic subjects. <i>Lancet</i> , The, 1994, 344, 305-306.	13.7	78
123	Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. <i>Thrombosis Research</i> , 2008, 123, 374-380.	1.7	78
124	Reduction in Visceral Adipose Tissue Is Associated with Improvement in Apolipoprotein B-100 Metabolism in Obese Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2854-2861.	3.6	78
125	Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. <i>Diabetic Medicine</i> , 2005, 22, 239-242.	2.3	77
126	Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (<sc>PCSK9</sc>) concentrations: a systematic review and meta-analysis of clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1042-1055.	4.4	77



#	ARTICLE	IF	CITATIONS
127	Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. American Journal of Cardiology, 2002, 90, 1254-1257.	1.6	76
128	Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2007, 4, 89-102.	2.0	76
129	Sterol 27-Hydroxylase Acts on 7-Ketocholesterol in Human Atherosclerotic Lesions and Macrophages in Culture. Journal of Biological Chemistry, 2000, 275, 27627-27633.	3.4	75
130	Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. Journal of Clinical Lipidology, 2015, 9, 703-708.	1.5	75
131	Endothelial dysfunction in Type 1 diabetic subjects with and without microalbuminuria. Diabetic Medicine, 1999, 16, 841-847.	2.3	74
132	Insulin Resistance, Inflammation, and Blood Pressure Determine Vascular Dysfunction in CKD. American Journal of Kidney Diseases, 2006, 48, 926-934.	1.9	74
133	Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 590-596.	2.4	72
134	Increased Hepatic Secretion of Very-Low-Density Lipoprotein Apolipoprotein B-100 in Obesity: A Stable Isotope Study. Clinical Science, 1995, 88, 225-233.	4.3	71
135	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 5, .	3.7	71
136	A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacological Research, 2019, 150, 104413.	7.1	70
137	Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. , 1997, 14, 974-978.		69
138	Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. European Journal of Clinical Investigation, 1999, 29, 204-209.	3.4	69
139	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
140	Serum Lipids and Lipoproteins in Insulinâ€dependent Diabetic Patients with Persistent Microalbuminuria. Diabetic Medicine, 1989, 6, 25-30.	2.3	68
141	Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-Î Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1568-E1576.	3.6	68
142	Effects of exercise training on conduit and resistance vessel function in treated and untreated hypercholesterolaemic subjects. European Heart Journal, 2003, 24, 1681-1689.	2.2	67
143	Revisiting the metabolic syndrome. Medical Journal of Australia, 2006, 185, 445-449.	1.7	67
144	Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus. Drugs, 2005, 65, 31-74.	10.9	66

#	ARTICLE	IF	CITATIONS
145	Prevalence and treatment of familial hypercholesterolaemia in Australian communities. International Journal of Cardiology, 2015, 185, 69-71.	1.7	66
146	Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2015, 201, 633-638.	1.7	66
147	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis, 2015, 239, 93-100.	0.8	65
148	Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Medicine, 2017, 15, 22.	5.5	65
149	Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis, 1995, 113, 79-89.	0.8	64
150	Hemodynamic Effects of Fenofibrate and Coenzyme Q10 in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction. Diabetes Care, 2008, 31, 1502-1509.	8.6	63
151	Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?. Clinical Chemistry, 2009, 55, 2049-2052.	3.2	63
152	Patients' Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment. International Journal of Behavioral Medicine, 2015, 22, 92-100.	1.7	63
153	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. Progress in Lipid Research, 2017, 68, 57-82.	11.6	63
154	Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 825-832.	0.5	62
155	An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?. International Journal of Clinical Practice, 2008, 62, 799-809.	1.7	62
156	Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 557-564.	3.6	62
157	Very Low Density Lipoprotein Metabolism and Plasma Adiponectin as Predictors of High-Density Lipoprotein Apolipoprotein A-I Kinetics in Obese and Nonobese Men. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 989-997.	3.6	62
158	Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. Journal of Lipid Research, 2009, 50, 2524-2531.	4.2	62
159	A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. International Journal of Cardiology, 2013, 167, 2391-2396.	1.7	62
160	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	1.7	62
161	Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis, 2012, 224, 430-434.	0.8	61
162	Docosahexaenoic Acid But Not Eicosapentaenoic Acid Increases LDL Particle Size in Treated Hypertensive Type 2 Diabetic Patients. Diabetes Care, 2003, 26, 253-253.	8.6	60

#	ARTICLE	IF	CITATIONS
163	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	1.8	60
164	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 13-30.	1.8	59
165	Dose-Dependent Effects of Rosuvastatin on the Plasma Sphingolipidome and Phospholipidome in the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2335-E2340.	3.6	59
166	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2218-2224.	2.4	58
167	Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein. <i>Circulation Research</i> , 2015, 116, 193-205.	4.5	58
168	Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. <i>Atherosclerosis</i> , 2008, 196, 823-834.	0.8	57
169	Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 1052-1057.	3.4	56
170	Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2008, 38, 743-751.	3.4	56
171	Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans. <i>Journal of Lipid Research</i> , 2006, 47, 1607-1619.	4.2	55
172	The erectile endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 263-273.	3.3	55
173	A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. <i>Clinical Nutrition</i> , 2016, 35, 331-336.	5.0	55
174	Prevalence of Familial Hypercholesterolemia in Adolescents: Potential Value of Universal Screening?. <i>Journal of Pediatrics</i> , 2016, 170, 315-316.	1.8	55
175	Experimental and clinical pharmacology: PCSK9 inhibitors - mechanisms of action. <i>Australian Prescriber</i> , 2016, 39, 164-167.	1.0	55
176	Ansoff's Matrix, pain and gain. <i>International Journal of Entrepreneurial Behaviour and Research</i> , 1998, 4, 101-111.	3.8	54
177	The Effect of Alcohol Intake on Insulin Sensitivity in Men: A randomized controlled trial. <i>Diabetes Care</i> , 2003, 26, 608-612.	8.6	54
178	High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 973-979.	3.6	54
179	MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 181-189.	3.4	54
180	Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. <i>Current Opinion in Lipidology</i> , 2006, 17, 28-36.	2.7	53

#	ARTICLE	IF	CITATIONS
181	Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. <i>Journal of Lipid Research</i> , 2011, 52, 794-800.	4.2	53
182	Nonalcoholic Fatty Liver Disease as the Transducer of Hepatic Oversecretion of Very-Low-Density Lipoproteinâ€“Apolipoprotein B-100 in Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1043-1050.	2.4	52
183	Opportunistic screening for familial hypercholesterolaemia via a community laboratory. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 534-537.	1.6	51
184	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. <i>Heart Lung and Circulation</i> , 2021, 30, 324-349.	0.4	51
185	Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 136-141.	3.4	50
186	Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 698-702.	4.4	50
187	Familial Hypercholesterolaemia in Primary Care: Knowledge and Practices among General Practitioners in Western Australia. <i>Heart Lung and Circulation</i> , 2014, 23, 309-313.	0.4	50
188	A new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practice. <i>Heart</i> , 2016, 102, 855-861.	2.9	50
189	Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. <i>Heart Lung and Circulation</i> , 2016, 25, 520-525.	0.4	50
190	A Randomized Trial of the Effect of Statin and Fibrate Therapy on Arterial Function in CKD. <i>American Journal of Kidney Diseases</i> , 2007, 49, 776-785.	1.9	49
191	Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1831-1837.	2.4	49
192	Regulation of plasma LDL: the apoB paradigm. <i>Clinical Science</i> , 2010, 118, 333-339.	4.3	49
193	Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services. <i>Heart Lung and Circulation</i> , 2014, 23, 1158-1164.	0.4	49
194	Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1290-1297.	2.8	49
195	Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2018, 8, 17887.	3.3	48
196	MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 967-981.	8.7	48
197	Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies. <i>Journal of Clinical Medicine</i> , 2019, 8, 118.	2.4	48
198	Simvastatin decreases the hepatic secretion of veryâ€“lowâ€“density lipoprotein apolipoprotein Bâ€“100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. <i>European Journal of Clinical Investigation</i> , 1995, 25, 559-567.	3.4	47

#	ARTICLE	IF	CITATIONS
199	Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. <i>International Journal of Obesity</i> , 2003, 27, 862-865.	3.4	47
200	Coenzyme Q <sub>10</sub> , endothelial function, and cardiovascular disease. <i>BioFactors</i> , 2011, 37, 366-373.	5.4	47
201	Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes. <i>AAPS PharmSciTech</i> , 2015, 16, 45-52.	3.3	47
202	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.8	47
203	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1329-1337.e3.	1.5	46
204	Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. <i>Journal of Internal Medicine</i> , 2020, 287, 746-747.	6.0	46
205	PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154221.	3.4	46
206	The urinary excretion of albumin in normal pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1987, 94, 408-412.	2.3	45
207	Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 2220-2225.	0.7	45
208	Statin therapy improves brachial artery endothelial function in nephrotic syndrome. <i>Kidney International</i> , 2002, 62, 550-557.	5.2	45
209	Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100-Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2686-2693.	2.4	45
210	Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 430-437.	3.6	44
211	Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. <i>Drugs</i> , 2015, 75, 1715-1724.	10.9	44
212	Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. <i>Journal of the American Heart Association</i> , 2015, 4, e002258.	3.7	44
213	Correlates of physical activity in people living with psychotic illness. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 129-137.	4.5	44
214	SPECIAL ARTICLE: NON-INVASIVE MEASUREMENT OF ENDOTHELIAL FUNCTION. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998, 25, 640-643.	1.9	43
215	Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2283-2289.	3.6	43
216	Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. <i>Vascular Health and Risk Management</i> , 2012, 8, 651.	2.3	43

#	ARTICLE	IF	CITATIONS
217	Dietary fatty acids and lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2013, 24, 192-197.	2.7	43
218	Effects of alcohol intake on endothelial function in men. <i>Journal of Hypertension</i> , 2003, 21, 97-103.	0.5	42
219	Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. <i>Clinical Science</i> , 2004, 107, 221-232.	4.3	42
220	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. <i>Clinical Science</i> , 2004, 107, 233-249.	4.3	42
221	High-density Lipoprotein Apolipoprotein A-II Kinetics in Obesity. <i>Obesity</i> , 2005, 13, 1008-1016.	4.0	42
222	Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. <i>Atherosclerosis</i> , 2008, 197, 732-739.	0.8	42
223	Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial. <i>Cardiovascular Diabetology</i> , 2011, 10, 102.	6.8	42
224	Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: A pilot study. <i>Journal of Clinical Lipidology</i> , 2015, 9, 42-48.	1.5	42
225	Systematic Detection of Familial Hypercholesterolaemia in Primary Health Care: A Community Based Prospective Study of Three Methods. <i>Heart Lung and Circulation</i> , 2015, 24, 250-256.	0.4	42
226	Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis from the General Population, by Age and Gender. <i>PLoS ONE</i> , 2013, 8, e82606.	2.5	41
227	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1704-1714.	3.6	41
228	The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2018, 136, 1-8.	1.9	41
229	Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. <i>Scientific Reports</i> , 2020, 10, 106.	3.3	41
230	Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. <i>Current Opinion in Lipidology</i> , 1996, 7, 341-355.	2.7	40
231	Inadequate fruit and vegetable intake in people with psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 1025-1035.	2.3	40
232	Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e011781.	3.7	40
233	Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154375.	3.4	40
234	Human lymphocyte sodium-hydrogen exchange. The influences of lipids, membrane fluidity, and insulin.. <i>Hypertension</i> , 1993, 21, 344-352.	2.7	39



#	ARTICLE	IF	CITATIONS
235	Familial lipoprotein lipase (LPL) deficiency: A catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. <i>Human Mutation</i> , 1997, 10, 465-473.	2.5	39
236	Leukocyte count and vascular function in Type 2 diabetic subjects with treated hypertension. <i>Atherosclerosis</i> , 2002, 163, 175-181.	0.8	39
237	Detection of Familial Hypercholesterolaemia: A Major Treatment Gap in Preventative Cardiology. <i>Heart Lung and Circulation</i> , 2008, 17, 411-413.	0.4	39
238	Inter-relationships between proprotein convertase subtilisin/kexin type-9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. <i>Clinical Science</i> , 2015, 128, 379-385.	4.3	39
239	Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 807-818.	2.4	39
240	Knowns and unknowns in the care of pediatric familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2017, 58, 1765-1776.	4.2	39
241	Lipoprotein(a): Knowns, unknowns and uncertainties. <i>Pharmacological Research</i> , 2021, 173, 105812.	7.1	39
242	Familial hypercholesterolemia: a missed opportunity in preventive medicine. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 404-405.	3.3	38
243	Erectile dysfunction predicts generalised cardiovascular disease: Evidence from a case-control study. <i>Atherosclerosis</i> , 2007, 194, 458-464.	0.8	38
244	Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. <i>Atherosclerosis</i> , 2008, 197, 139-146.	0.8	38
245	Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors. <i>International Journal of Behavioral Medicine</i> , 2016, 23, 282-294.	1.7	38
246	Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part. <i>Atherosclerosis</i> , 2018, 277, 399-406.	0.8	38
247	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	1.7	38
248	Vascular function of the peripheral circulation in patients with nephrosis. <i>Kidney International</i> , 2001, 60, 182-189.	5.2	37
249	Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type-2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2003, 58, 415-420.	2.4	37
250	Carotid intima-medial thickness measured on multiple ultrasound frames: evaluation of a DICOM-based software system. <i>Cardiovascular Ultrasound</i> , 2007, 5, 29.	1.6	37
251	Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type-2 diabetic patients. <i>Clinical Science</i> , 2010, 118, 607-615.	4.3	37
252	Fibrate therapy and circulating adiponectin concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Atherosclerosis</i> , 2013, 230, 110-120.	0.8	37



#	ARTICLE	IF	CITATIONS
253	Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?. Expert Opinion on Drug Safety, 2014, 13, 1227-1239.	2.4	37
254	Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?. Clinical Chemistry, 2019, 65, 1258-1266.	3.2	37
255	Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research, 2002, 43, 706-712.	4.2	37
256	Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. European Journal of Clinical Investigation, 2001, 31, 113-117.	3.4	36
257	Oxidant stress in nephrotic syndrome: comparison of F2â€isoprostanes and plasma antioxidant potential. Nephrology Dialysis Transplantation, 2001, 16, 1626-1630.	0.7	36
258	NDRG1 interacts with APO A-I and A-II and is a functional candidate for the HDL-C QTL on 8q24. Biochemical and Biophysical Research Communications, 2005, 332, 982-992.	2.1	36
259	Polymorphism of the follistatin gene in polycystic ovary syndrome. Molecular Human Reproduction, 2007, 13, 237-241.	2.8	36
260	Dose-Dependent Effect of Rosuvastatin on VLDLâ€™Apolipoprotein C-III Kinetics in the Metabolic Syndrome. Diabetes Care, 2008, 31, 1656-1661.	8.6	36
261	Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver disease. Clinical Science, 2008, 114, 543-545.	4.3	36
262	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Atherosclerosis, 2014, 232, 410-413.	0.8	36
263	Translational Research for Improving the Care of Familial Hypercholesterolemia: The â€™Ten Countries Studyâ€™and Beyond. Journal of Atherosclerosis and Thrombosis, 2016, 23, 891-900.	2.0	36
264	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. Clinical Cardiology, 2018, 41, 378-384.	1.8	36
265	Health literacy in familial hypercholesterolemia: A cross-national study. European Journal of Preventive Cardiology, 2018, 25, 936-943.	1.8	36
266	Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs, 2018, 78, 99-109.	10.9	36
267	Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?. Atherosclerosis, 2020, 304, 1-8.	0.8	36
268	Early Recycling Compartment Trafficking of CD1a Is Essential for Its Intersection and Presentation of Lipid Antigens. Journal of Immunology, 2010, 184, 1235-1241.	0.8	35
269	Apolipoprotein A-II: Evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis. Annals of Medicine, 2012, 44, 313-324.	3.8	35
270	Measurement and application of arterial stiffness in clinical research: focus on new methodologies and diabetes mellitus. Medical Science Monitor, 2003, 9, RA81-9.	1.1	35

#	ARTICLE	IF	CITATIONS
271	Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance. <i>Clinical Science</i> , 2003, 105, 537-540.	4.3	34
272	Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 612-617.	4.4	34
273	Dissociation of endothelial function and arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , 2009, 71, 808-814.	2.4	33
274	The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies. <i>International Journal of Cardiology</i> , 2013, 168, 1811-1818.	1.7	33
275	Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. <i>Clinica Chimica Acta</i> , 2013, 422, 21-25.	1.1	33
276	An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study". <i>BMJ Open</i> , 2017, 7, e017817.	1.9	33
277	Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2021, 42, 2201-2211.	2.2	33
278	Apolipoprotein B independently predicts progression of very low-level albuminuria in insulin-dependent diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1101-1107.	3.4	32
279	Relationships between cholesterol homeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. <i>Clinical Science</i> , 2003, 104, 383.	4.3	32
280	The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 381-389.	4.4	32
281	Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 752-756.	4.4	32
282	Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1221.	4.3	32
283	Plasma Apolipoprotein B-48 Transport in Obese Men: A New Tracer Kinetic Study in the Postprandial State. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E122-E126.	3.6	32
284	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 369-385.	4.7	32
285	Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. <i>International Journal of Cardiology</i> , 2015, 201, 79-84.	1.7	32
286	Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 472.	4.8	32
287	n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease. <i>Nutrients</i> , 2016, 8, 175.	4.1	32
288	In search of the vulnerable patient or the vulnerable plaque: 18F-sodium fluoride positron emission tomography for cardiovascular risk stratification. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 1774-1783.	2.1	32

#	ARTICLE	IF	CITATIONS
289	Comparative aspects of the care of familial hypercholesterolemia in the “Ten Countries Study”. Journal of Clinical Lipidology, 2019, 13, 287-300.	1.5	32
290	Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. Journal of Lipid Research, 2002, 43, 344-349.	4.2	32
291	Cardiovascular risk factors and endothelial dysfunction. Clinical Science, 2004, 107, 609-615.	4.3	31
292	Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. Current Opinion in Lipidology, 2017, 28, 495-501.	2.7	31
293	Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 281, 25-30.	0.8	31
294	von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet. Journal of Internal Medicine, 1995, 237, 557-561.	6.0	30
295	Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry, 2014, 13, 176-183.	10.4	30
296	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 387-403.	4.7	30
297	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. Journal of Clinical Lipidology, 2018, 12, 1358-1366.	1.5	30
298	Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1644-1655.	2.4	30
299	World Heart Federation Cholesterol Roadmap. Global Heart, 2017, 12, 179.	2.3	30
300	Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease. Journal of the American Heart Association, 2020, 9, e015355.	3.7	30
301	Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. Journal of Lipid Research, 2002, 43, 344-9.	4.2	30
302	Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research, 2002, 43, 706-12.	4.2	30
303	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nature Communications, 2022, 13, .	12.8	30
304	Kinetics of very-low-density lipoprotein apolipoprotein B-100 in normolipidemic subjects: Pooled analysis of stable-isotope studies. Metabolism: Clinical and Experimental, 2000, 49, 1204-1210.	3.4	29
305	Can coenzyme Q <sub>10</sub> improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. BioFactors, 2003, 18, 129-136.	5.4	29
306	Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism: Clinical and Experimental, 2003, 52, 1279-1286.	3.4	29

#	ARTICLE	IF	CITATIONS
307	Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton, Western Australia. <i>Annals of Epidemiology</i> , 2004, 14, 627-632.	1.9	29
308	Familial hypercholesterolaemia: PCSK9 inhibitors are coming. <i>Lancet</i> , The, 2015, 385, 307-310.	13.7	29
309	International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 505-519.	2.0	29
310	Î‰-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3732-3739.	3.6	29
311	Increasing the Detection of Familial Hypercholesterolaemia Using General Practice Electronic Databases. <i>Heart Lung and Circulation</i> , 2017, 26, 450-454.	0.4	29
312	Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 1075-1084.	2.0	29
313	Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study. <i>Journal of Lipid Research</i> , 2020, 61, 537-545.	4.2	29
314	Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiotensin-like Protein 3, in Patients With Hypercholesterolemia. <i>Circulation</i> , 2020, 142, .	1.6	29
315	ATP-Binding Cassette Transporter G8 Gene As a Determinant of Apolipoprotein B-100 Kinetics in Overweight Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2188-2191.	2.4	28
316	Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2006, 86, 1438-1446.	1.0	28
317	Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. <i>Clinical Science</i> , 2006, 111, 193-199.	4.3	28
318	Metabolic syndrome and cardiometabolic risk in PCOS. <i>Current Diabetes Reports</i> , 2007, 7, 66-73.	4.2	28
319	Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2009, 85, 310-316.	2.8	28
320	Role of international registries in enhancing the care of familial hypercholesterolaemia. <i>International Journal of Evidence-Based Healthcare</i> , 2013, 11, 134-139.	0.5	28
321	Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator-Activated Receptor Î±-Dependent and Independent Mechanisms in Human Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 621-628.	2.4	28
322	Effect of Niacin on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Statin-Treated Patients With Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 427-432.	2.4	28
323	Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2015, 242, 226-229.	0.8	28
324	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. <i>Nature Reviews Endocrinology</i> , 2016, 12, 467-484.	9.6	28

#	ARTICLE	IF	CITATIONS
325	Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 682-693.	1.5	28
326	Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1019-1026.	1.5	28
327	Plasma Markers of Cholesterol Homeostasis and Apolipoprotein Bâ€100 Kinetics in the Metabolic Syndrome. <i>Obesity</i> , 2003, 11, 591-596.	4.0	27
328	Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. <i>Current Opinion in Lipidology</i> , 2003, 14, 61-68.	2.7	27
329	Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. <i>Clinical Science</i> , 2003, 104, 383-388.	4.3	27
330	Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. , 2009, 123, 281-291.		27
331	Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. <i>Atherosclerosis</i> , 2010, 210, 326-330.	0.8	27
332	Screening for familial hypercholesterolaemia. <i>Pathology</i> , 2012, 44, 122-128.	0.6	27
333	An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic) Tj ETQq1 1 0,784314 rgBT /Ove	4.3	27
334	Detecting familial hypercholesterolaemia in the community: Impact of a telephone call from a chemical pathologist to the requesting general practitioner. <i>Atherosclerosis</i> , 2014, 234, 469-472.	0.8	27
335	A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. <i>Drug Discovery Today</i> , 2020, 25, 58-72.	6.4	27
336	Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 415-419.	3.4	26
337	Independent Correlation Between Plasma Lipoprotein(a) and Angiographic Coronary Artery Disease in NIDDM. <i>Diabetes Care</i> , 1995, 18, 234-236.	8.6	26
338	Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. <i>Clinica Chimica Acta</i> , 2001, 306, 63-69.	1.1	26
339	Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. <i>Diabetic Medicine</i> , 2005, 22, 1558-1565.	2.3	26
340	Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 296-299.	2.0	26
341	Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3543-3549.	0.7	26
342	Effect of 100-3 Fatty Acid Ethyl Esters on Apolipoprotein B-48 Kinetics in Obese Subjects on a Weight-Loss Diet: A New Tracer Kinetic Study in the Postprandial State. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1427-E1435.	3.6	26

#	ARTICLE	IF	CITATIONS
343	Recent advances in demystifying the metabolism of lipoprotein(a). <i>Atherosclerosis</i> , 2022, 349, 82-91.	0.8	26
344	Management of patients with severe hypertriglyceridaemia during pregnancy: report of two cases with familial lipoprotein lipase deficiency. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1992, 99, 163-166.	2.3	25
345	Effects of atorvastatin and n <sup>3</sup> fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 900-906.	4.7	25
346	Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. <i>International Journal of Evidence-Based Healthcare</i> , 2012, 10, 211-221.	0.5	25
347	Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: Effect of fenofibrate treatment. <i>Atherosclerosis</i> , 2012, 221, 484-489.	0.8	25
348	An online questionnaire survey of UK general practitioners' knowledge and management of familial hypercholesterolaemia. <i>BMJ Open</i> , 2016, 6, e012691.	1.9	25
349	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	3.3	25
350	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. <i>European Heart Journal</i> , 2018, 39, 3635-3640.	2.2	25
351	Improving clinical practice guidelines with implementation science. <i>Nature Reviews Cardiology</i> , 2022, 19, 3-4.	13.7	25
352	HDL metabolism in context: looking on the bright side. <i>Current Opinion in Lipidology</i> , 2008, 19, 395-404.	2.7	24
353	Severe HDL deficiency due to novel defects in the ABCA1 transporter. <i>Journal of Internal Medicine</i> , 2009, 265, 359-372.	6.0	24
354	Familial hypercholesterolaemia in children and adolescents: A new paediatric model of care. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, E263-72.	0.8	24
355	Can Patients be Accurately Assessed for Familial Hypercholesterolaemia in Primary Care?. <i>Heart Lung and Circulation</i> , 2014, 23, 1153-1157.	0.4	24
356	Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2497-2501.	3.6	24
357	Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. <i>Clinical Cardiology</i> , 2018, 41, 159-165.	1.8	24
358	Recent advances in synthetic pharmacotherapies for dyslipidaemias. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1576-1596.	1.8	24
359	The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 64.	4.8	24
360	Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. <i>Atherosclerosis</i> , 2001, 157, 519-523.	0.8	23



#	ARTICLE	IF	CITATIONS
361	Effect of laparoscopic sleeve gastrectomy on elevated C-reactive protein and atherogenic dyslipidemia in morbidly obese patients. <i>Clinical Biochemistry</i> , 2011, 44, 342-344.	1.9	23
362	Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 3-11.	3.4	23
363	n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease. <i>Journal of Hypertension</i> , 2015, 33, 1947-1953.	0.5	23
364	Carotid artery plaques and intima medial thickness in familial hypercholesterolaemic patients on long-term statin therapy: A case control study. <i>Atherosclerosis</i> , 2017, 256, 62-66.	0.8	23
365	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2019, 17, 538-540.	1.7	23
366	Postprandial lipaemia in familial hypercholesterolaemia: clinical and metabolic significance. <i>Atherosclerosis</i> , 2000, 148, 426-428.	0.8	22
367	Conservation of CD1 Intracellular Trafficking Patterns Between Mammalian Species. <i>Journal of Immunology</i> , 2002, 169, 6951-6958.	0.8	22
368	Adipose tissue compartments and insulin resistance in overweight-obese Caucasian men. <i>Diabetes Research and Clinical Practice</i> , 2004, 63, 77-85.	2.8	22
369	A New Model of Care for Familial Hypercholesterolaemia from Western Australia: Closing a Major Gap in Preventive Cardiology. <i>Heart Lung and Circulation</i> , 2010, 19, 419-422.	0.4	22
370	Apolipoprotein B-100 and ApoA-II Kinetics as Determinants of Cellular Cholesterol Efflux. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1658-E1666.	3.6	22
371	Insulin Resistance and the Metabolic Syndrome Are Associated With Arterial Stiffness in Patients With Chronic Kidney Disease. <i>American Journal of Hypertension</i> , 2013, 26, 1155-1161.	2.0	22
372	Interrelationships Between the Kinetics of VLDL Subspecies and HDL Catabolism in Abdominal Obesity: A Multicenter Tracer Kinetic Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4281-4290.	3.6	22
373	Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. <i>Lancet Psychiatry</i> , 2015, 2, 1092-1098.	7.4	22
374	Interpreting Community-Based Enterprise: A Case Study from Rural Wales. <i>Journal of Social Entrepreneurship</i> , 2016, 7, 211-235.	2.5	22
375	PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 270-282.	4.4	22
376	A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 608-617.	1.5	22
377	Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application. <i>Heart Lung and Circulation</i> , 2020, 29, 619-633.	0.4	22
378	Practical Guidance for Food Consumption to Prevent Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2021, 30, 163-179.	0.4	22



#	ARTICLE	IF	CITATIONS
379	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. <i>European Heart Journal</i> , 2022, 43, 3243-3254.	2.2	22
380	Long-term variation of urinary albumin excretion in insulin-dependent diabetes mellitus: some practical recommendations for monitoring microalbuminuria. <i>Diabetes Research and Clinical Practice</i> , 1990, 9, 169-177.	2.8	21
381	Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma. <i>Journal of Lipid Research</i> , 2006, 47, 1274-1280.	4.2	21
382	Of Mice and Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1892-1895.	2.4	21
383	Postprandial dyslipidaemia and diabetes. <i>Current Opinion in Lipidology</i> , 2012, 23, 303-309.	2.7	21
384	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. <i>Clinical Science</i> , 2015, 129, 63-79.	4.3	21
385	MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 878-883.	2.0	21
386	Common familial risk factors for schizophrenia and diabetes mellitus. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 488-494.	2.3	21
387	Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). <i>European Heart Journal</i> , 2017, 38, 3555-3559.	2.2	21
388	Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque. <i>Atherosclerosis</i> , 2018, 275, 232-238.	0.8	21
389	Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. <i>Clinical Chemistry</i> , 2002, 48, 278-83.	3.2	21
390	Detecting familial hypercholesterolaemia in general practice. <i>Australian Family Physician</i> , 2012, 41, 965-8.	0.5	21
391	Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in Type 2 diabetes: Associations with blood pressure and HDL cholesterol. <i>Diabetes Research and Clinical Practice</i> , 2006, 71, 59-67.	2.8	20
392	Statins and Metabolism of High Density Lipoprotein. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2007, 5, 215-221.	1.0	20
393	Metabolic syndrome in people with a psychotic illness: is cannabis protective?. <i>Psychological Medicine</i> , 2016, 46, 1651-1662.	4.5	20
394	Loneliness in psychotic illness and its association with cardiometabolic disorders. <i>Schizophrenia Research</i> , 2019, 204, 90-95.	2.0	20
395	Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2. <i>BMC Infectious Diseases</i> , 2021, 21, 580.	2.9	20
396	Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2007, 16, 624-31.	0.4	20

#	ARTICLE	IF	CITATIONS
397	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 182, 552-553.	1.7	19
398	Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes, Obesity and Metabolism, 2014, 16, 780-792.	4.4	19
399	Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. Atherosclerosis, 2015, 242, 295-302.	0.8	19
400	Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1140-1145.	2.6	19
401	The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats. Current Atherosclerosis Reports, 2018, 20, 31.	4.8	19
402	Lipid management in people with peripheral artery disease. Current Opinion in Lipidology, 2019, 30, 470-476.	2.7	19
403	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. Current Vascular Pharmacology, 2019, 17, 515-537.	1.7	19
404	Exercise Testing as a Long-Term Predictor of the Development of Microalbuminuria in Normoalbuminuric IDDM Patients. Diabetes Care, 1995, 18, 1602-1605.	8.6	18
405	The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Clinical Science, 2002, 103, 595-597.	4.3	18
406	Fat Compartments and Apolipoprotein B-100 Kinetics in Overweight-Obese Men. Obesity, 2003, 11, 152-159.	4.0	18
407	Cytomegalovirus antibody and vascular pathology in renal transplant recipients. Journal of Medical Virology, 2017, 89, 177-181.	5.0	18
408	Parent-child genetic testing for familial hypercholesterolaemia in an Australian context. Journal of Paediatrics and Child Health, 2018, 54, 741-747.	0.8	18
409	Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. Atherosclerosis, 2018, 277, 493-501.	0.8	18
410	Response by Ward et al to Letter Regarding Article, "Statin Toxicity: Mechanistic Insights and Clinical Implications". Circulation Research, 2019, 124, e121-e122.	4.5	18
411	Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease. JACC: Cardiovascular Imaging, 2021, 14, 1206-1217.	5.3	18
412	Direct association between the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man. Atherosclerosis, 1997, 135, 83-91.	0.8	17
413	Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. , 2001, 2, 118.		17
414	Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. Clinical Science, 2013, 125, 45-51.	4.3	17

#	ARTICLE	IF	CITATIONS
415	Supplementation with n3 Fatty Acid Ethyl Esters Increases Large and Small Artery Elasticity in Obese Adults on a Weight Loss Diet. <i>Journal of Nutrition</i> , 2013, 143, 437-441.	2.9	17
416	The doctor's dilemma: Challenges in the diagnosis and care of homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2014, 8, 542-549.	1.5	17
417	Coronary artery calcium scoring in cardiovascular risk assessment of people with family histories of early onset coronary artery disease. <i>Medical Journal of Australia</i> , 2020, 213, 170-177.	1.7	17
418	Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods. <i>Current Opinion in Lipidology</i> , 2020, 31, 347-355.	2.7	17
419	The effect of Vitamin-K1 and Colchicine on Vascular Calcification Activity in subjects with Diabetes Mellitus (ViKCoVaC): A double-blind 2x2 factorial randomized controlled trial. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1855-1866.	2.1	17
420	The use of random urine samples to screen for microalbuminuria in the diabetic clinic. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1986, 3, 86-88.	0.2	16
421	Endothelial dysfunction, insulin resistance and diabetes: exploring the web of causality. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 523-534.	0.5	16
422	Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. <i>Clinical Endocrinology</i> , 2008, 69, 45-51.	2.4	16
423	Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome. <i>Diabetes Care</i> , 2009, 32, 2111-2113.	8.6	16
424	A New Model of Care for Familial Hypercholesterolaemia: What is the Role of Cardiology?. <i>Heart Lung and Circulation</i> , 2012, 21, 543-550.	0.4	16
425	A Web-Based Registry for Familial Hypercholesterolaemia. <i>Heart Lung and Circulation</i> , 2017, 26, 635-639.	0.4	16
426	Lipoprotein apheresis downregulates IL-1 $\beta$ , IL-6 and TNF- $\alpha$ mRNA expression in severe dyslipidaemia. <i>Atherosclerosis Supplements</i> , 2017, 30, 200-208.	1.2	16
427	The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension. <i>Current Hypertension Reports</i> , 2017, 19, 99.	3.5	16
428	Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome. <i>Diabetic Medicine</i> , 2019, 36, 1643-1651.	2.3	16
429	Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6247-6255.	3.6	16
430	Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 580-585.	1.5	16
431	Origin and therapy for hypertriglyceridaemia in type 2 diabetes. <i>World Journal of Diabetes</i> , 2014, 5, 165.	3.5	16
432	<i>APOE</i> $\epsilon$ 2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. <i>Alzheimer's and Dementia</i> , 2022, 18, 2151-2166.	0.8	16

#	ARTICLE	IF	CITATIONS
433	Urinary Infection and Albumin Excretion in Insulin-dependent Diabetes Mellitus: Implications for the Measurement of Microalbuminuria. <i>Diabetic Medicine</i> , 1996, 13, 520-524.	2.3	15
434	Familial lipoprotein lipase deficiency caused by known (G188E) and novel (W394X) LPL gene mutations. <i>Annals of Clinical Biochemistry</i> , 2008, 45, 102-105.	1.6	15
435	Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome. <i>Clinical Science</i> , 2010, 118, 79-85.	4.3	15
436	Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. <i>Journal of Lipid Research</i> , 2012, 53, 2443-2449.	4.2	15
437	Progress in the care of familial hypercholesterolaemia: 2016. <i>Medical Journal of Australia</i> , 2016, 205, 232-236.	1.7	15
438	Risk Factors for Obstructive Sleep Apnea Are Prevalent in People with Psychosis and Correlate with Impaired Social Functioning and Poor Physical Health. <i>Frontiers in Psychiatry</i> , 2016, 7, 139.	2.6	15
439	Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies. <i>Current Opinion in Lipidology</i> , 2017, 28, 321-327.	2.7	15
440	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. <i>Journal of Clinical Medicine</i> , 2019, 8, 2073.	2.4	15
441	Influence of an asparagine to lysine mutation at amino acid 3516 of apolipoprotein B on low-density lipoprotein receptor binding. <i>Clinica Chimica Acta</i> , 2002, 321, 113-121.	1.1	14
442	Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfv326.	0.7	14
443	Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1188-1194.	1.5	14
444	The association between chronic hepatitis C infection and cardiovascular risk. <i>Internal Medicine Journal</i> , 2016, 46, 63-70.	0.8	14
445	Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?. <i>European Heart Journal</i> , 2016, 37, 1353-1356.	2.2	14
446	New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1200-1205.	1.8	14
447	Rationale and design of a trial to personalize risk assessment in familial coronary artery disease. <i>American Heart Journal</i> , 2018, 199, 22-30.	2.7	14
448	Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training. <i>Atherosclerosis</i> , 2018, 277, 508-516.	0.8	14
449	<sup>18</sup> F-Sodium Fluoride Positron Emission Tomography Activity Predicts the Development of New Coronary Artery Calcifications. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 534-541.	2.4	14
450	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2020, 298, 52-57.	0.8	14

#	ARTICLE	IF	CITATIONS
451	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. <i>Heart Lung and Circulation</i> , 2021, 30, 372-379.	0.4	14
452	Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a doseâ€“response model. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 578-586.	3.0	14
453	The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 45-52.	4.7	14
454	Management of Lipid Disorders in the Elderly. <i>Drugs and Aging</i> , 1997, 10, 444-462.	2.7	13
455	Postprandial dyslipidaemia in a nutshell: food for thought. <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 816-823.	0.5	13
456	FISH OILS, PHYTOSTEROLS AND WEIGHT LOSS IN THE REGULATION OF LIPOPROTEIN TRANSPORT IN THE METABOLIC SYNDROME: LESSONS FROM STABLE ISOTOPE TRACER STUDIES. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2006, 33, 877-882.	1.9	13
457	Challenges in the care of familial hypercholesterolemia: a community care perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1091-1100.	1.5	13
458	The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. <i>Clinica Chimica Acta</i> , 2015, 448, 18-21.	1.1	13
459	ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?. <i>European Heart Journal</i> , 2016, 37, 3596-3599.	2.2	13
460	Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia. <i>Pathology</i> , 2016, 48, 463-466.	0.6	13
461	Reverse cascade screening for familial hypercholesterolemia in highâ€“risk Chinese families. <i>Clinical Cardiology</i> , 2017, 40, 1169-1173.	1.8	13
462	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. <i>Cardiology Clinics</i> , 2018, 36, 287-298.	2.2	13
463	Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study. <i>Social Science and Medicine</i> , 2019, 242, 112591.	3.8	13
464	Identifying Perceptions and Preferences of the General Public Concerning Universal Screening of Children for Familial Hypercholesterolaemia. <i>Public Health Genomics</i> , 2019, 22, 25-35.	1.0	13
465	Improving the detection of familial hypercholesterolaemia. <i>Pathology</i> , 2019, 51, 213-221.	0.6	13
466	Mental health recovery and physical health outcomes in psychotic illness: Longitudinal data from the Western Australian survey of high impact psychosis catchments. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 55, 000486742095426.	2.3	13
467	Improving detection and management of familial hypercholesterolaemia in Australian general practice. <i>Heart</i> , 2021, 107, 1213-1219.	2.9	13
468	Lipoprotein (a) and diabetes mellitus: causes and consequences. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 181-187.	2.3	13

#	ARTICLE	IF	CITATIONS
469	Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. <i>Future Cardiology</i> , 2022, 18, 143-153.	1.2	13
470	A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. <i>Clinical Biochemist Reviews</i> , 2012, 33, 25-31.	3.3	13
471	Sideâ€room Tests to Screen for Microâ€albuminuria in Diabetes Mellitus. <i>Diabetic Medicine</i> , 1988, 5, 298-303.	2.3	12
472	An Acceptable Exercise Test to Study Microalbuminuria in Type 1 Diabetes. <i>Diabetic Medicine</i> , 1989, 6, 787-792.	2.3	12
473	Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase. <i>Atherosclerosis</i> , 1993, 103, 231-243.	0.8	12
474	Lipids, lipoproteins, antioxidants and glomerular and tubular dysfunction in type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 1996, 32, 81-90.	2.8	12
475	Regulation of Endothelial Nitric Oxide Synthase by PPAR Agonists: Molecular and Clinical Perspectives. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 619-621.	2.4	12
476	Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 501-505.	2.1	12
477	Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 328-336.	2.8	12
478	Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin. <i>Atherosclerosis</i> , 2016, 252, 82-87.	0.8	12
479	Mode of action of berberine on lipid metabolism: a newâ€old phytochemical with clinical applications?. <i>Current Opinion in Lipidology</i> , 2017, 28, 282-283.	2.7	12
480	Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. <i>Lipids in Health and Disease</i> , 2020, 19, 239.	3.0	12
481	Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology. <i>Current Opinion in Cardiology</i> , 2021, 36, 272-280.	1.8	12
482	Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , 2016, 22, 595-608.	1.9	12
483	A resilient type of familial hypercholesterolaemia: caseâ€control follow-up of genetically characterized older patients in the SAFEHEART cohort. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 795-801.	1.8	12
484	Angiotensin converting enzyme gene polymorphism and the course of angiographically defined coronary artery disease. <i>Atherosclerosis</i> , 1995, 114, 133-135.	0.8	11
485	Complete deficiency of plasma lecithin-cholesterol acyltransferase (LCAT) activity due to a novel homozygous mutation (Gly-30-Ser) in the LCAT gene. <i>Human Mutation</i> , 1996, 8, 79-82.	2.5	11
486	Effect of an acute hyperinsulinaemic clamp on post-prandial lipaemia in subjects with insulin resistance. <i>European Journal of Clinical Investigation</i> , 2006, 36, 489-496.	3.4	11



#	ARTICLE	IF	CITATIONS
487	INTERIM Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia. Heart Lung and Circulation, 2012, 21, 159-162.	0.4	11
488	Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. Diabetes, Obesity and Metabolism, 2014, 16, 519-526.	4.4	11
489	Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism: Clinical and Experimental, 2014, 63, 1071-1077.	3.4	11
490	Cardiovascular risk factor associations in adults with psychosis and adults in a national comparator sample. Australian and New Zealand Journal of Psychiatry, 2015, 49, 714-723.	2.3	11
491	Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis, 2015, 240, 284-296.	0.8	11
492	Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1505-1515.	3.3	11
493	Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. European Journal of Clinical Investigation, 2018, 49, e13053.	3.4	11
494	Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families. Atherosclerosis, 2018, 277, 392-398.	0.8	11
495	PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. European Journal of Preventive Cardiology, 2019, 26, 998-1000.	1.8	11
496	Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia. Clinica Chimica Acta, 2020, 510, 211-215.	1.1	11
497	The economic impact of familial hypercholesterolemia on productivity. Journal of Clinical Lipidology, 2020, 14, 799-806.e3.	1.5	11
498	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis, 2021, 320, 1-9.	0.8	11
499	Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia. Journal of Paediatrics and Child Health, 2022, 58, 281-287.	0.8	11
500	Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials. Review of Diabetic Studies, 2013, 10, 191-203.	1.3	11
501	Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis, 2022, 349, 160-165.	0.8	11
502	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). Atherosclerosis, 2022, 349, 219-226.	0.8	11
503	Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Frontiers in Genetics, 2022, 13, 905941.	2.3	11
504	Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia. European Journal of Clinical Investigation, 2002, 32, 493-499.	3.4	10



#	ARTICLE	IF	CITATIONS
505	LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study?. European Journal of Clinical Investigation, 2004, 34, 719-722.	3.4	10
506	Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men. Metabolism: Clinical and Experimental, 2011, 60, 1482-1487.	3.4	10
507	Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies. Clinical Lipidology, 2014, 9, 221-233.	0.4	10
508	Management of Familial Hypercholesterolemia in Hong Kong. Journal of Atherosclerosis and Thrombosis, 2016, 23, 520-531.	2.0	10
509	Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B kinetics in statin-treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 384-391.	4.4	10
510	Lipoprotein(a): lodestar for future clinical trials. Lancet, The, 2018, 392, 1281-1282.	13.7	10
511	Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration. Metabolism: Clinical and Experimental, 2019, 96, 8-11.	3.4	10
512	Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. Diabetes, Obesity and Metabolism, 2019, 21, 52-62.	4.4	10
513	The brave new world of genetic testing in the management of the dyslipidaemias. Current Opinion in Cardiology, 2020, 35, 226-233.	1.8	10
514	New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects. Frontiers in Physiology, 2021, 12, 603910.	2.8	10
515	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. Journal of Clinical Medicine, 2021, 10, 4930.	2.4	10
516	Population DNA screening for medically actionable disease risk in adults. Medical Journal of Australia, 2022, 216, 278-280.	1.7	10
517	Lipoprotein (a) and Hypertension. Current Hypertension Reports, 2021, 23, 44.	3.5	10
518	Homocysteine and nephrotic syndrome. Nephrology Dialysis Transplantation, 2001, 16, 1720-1721.	0.7	9
519	Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism. Atherosclerosis Supplements, 2002, 2, 1-4.	1.2	9
520	Balancing the cardiometabolic benefits and risks of statins. Lancet, The, 2012, 380, 541-543.	13.7	9
521	Association between skeletal muscle fat content and very-low-density lipoprotein apolipoprotein B transport in obesity: effect of weight loss. Diabetes, Obesity and Metabolism, 2014, 16, 994-1000.	4.4	9
522	Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a) lipoproteinemia. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	9

#	ARTICLE	IF	CITATIONS
523	Challenges in the health economics of familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2016, 27, 563-569.	2.7	9
524	Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1280-1289.	4.3	9
525	Triglyceride-rich lipoprotein metabolism in women: roles of apoB-II and apoB-III. <i>European Journal of Clinical Investigation</i> , 2016, 46, 730-736.	3.4	9
526	Registries, codifications and cardiovascular outcomes in familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 133-136.	1.8	9
527	The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia. <i>Medical Journal of Australia</i> , 2018, 208, 18-23.	1.7	9
528	Status of PCSK9 Monoclonal Antibodies in Australia. <i>Heart Lung and Circulation</i> , 2019, 28, 1571-1579.	0.4	9
529	Knowledge and Awareness of Familial Hypercholesterolaemia among Registered Medical Practitioners in Tamil Nadu: Are They Suboptimal?. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, OC52-6.	0.8	9
530	A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?. <i>BioDrugs</i> , 2022, 36, 121-135.	4.6	9
531	Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a). <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100343.	3.0	9
532	Comparison of the Real-time Use of Glycosylated Haemoglobin and Plasma Fructosamine in the Diabetic Clinic. <i>Diabetic Medicine</i> , 1991, 8, 573-579.	2.3	8
533	One year experience in the treatment of familial hypercholesterolaemia with simvastatin.. <i>Postgraduate Medical Journal</i> , 1992, 68, 575-580.	1.8	8
534	Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States. <i>Current Vascular Pharmacology</i> , 2008, 6, 67-77.	1.7	8
535	Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. <i>Postgraduate Medical Journal</i> , 2011, 87, 776-782.	1.8	8
536	Whither the Lipid Profile: Feast, Famine, or No Free Lunch?. <i>Clinical Chemistry</i> , 2011, 57, 363-365.	3.2	8
537	PCSK9 inhibition 2018: riding a new wave of coronary prevention. <i>Clinical Science</i> , 2019, 133, 205-224.	4.3	8
538	Familial Hypercholesterolemia in a Healthy Elderly Population. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002938.	3.6	8
539	Detection and management of familial hypercholesterolaemia in primary care in Australia: protocol for a pragmatic cluster intervention study with pre-post intervention comparisons. <i>BMJ Open</i> , 2017, 7, e017539.	1.9	8
540	Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia. <i>Circulation</i> , 2020, 142, .	1.6	8

#	ARTICLE	IF	CITATIONS
541	PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration. Journal of Internal Medicine, 2022, 291, 870-876.	6.0	8
542	Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study). BMJ Open, 2022, 12, e058826.	1.9	8
543	Filter paper spot blood glucose. Laboratory and patient methodology. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1985, 2, 41-44.	0.2	7
544	DETERMINANTS OF THE KINETICS OF VERY LOW-DENSITY LIPOPROTEIN APOLIPOPROTEIN B-100 IN NON-OBESE MEN. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 556-562.	1.9	7
545	Therapeutic considerations for postprandial dyslipidaemia. Diabetes, Obesity and Metabolism, 2001, 3, 143-156.	4.4	7
546	Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.6	7
547	Adipose tissue compartments and the kinetics of very[ndash ]low-density lipoprotein apolipoprotein B-100 in non-obese men. Metabolism: Clinical and Experimental, 2002, 51, 1206-1210.	3.4	7
548	Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. Clinical Biochemistry, 2005, 38, 806-812.	1.9	7
549	Nutrition and metabolism: non-alcoholic fatty liver disease " pathogenesis, cardiovascular risk and therapy. Current Opinion in Lipidology, 2008, 19, 92-94.	2.7	7
550	Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes. Atherosclerosis Supplements, 2010, 11, 61-64.	1.2	7
551	Thought for food: Clinical evidence for the dietary prevention strategy in cardiovascular disease. International Journal of Evidence-Based Healthcare, 2013, 11, 330-336.	0.5	7
552	Europe aspires to set the record straight on familial hypercholesterolaemia. Atherosclerosis, 2015, 241, 769-771.	0.8	7
553	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics, 2015, 37, 2732-2750.	2.5	7
554	Developing role of microRNA-33 in lipid metabolism and atherosclerosis. Current Opinion in Lipidology, 2016, 27, 197-199.	2.7	7
555	Counting up the risks: How common are risk factors for morbidity and mortality in young people with psychosis?. Microbial Biotechnology, 2018, 12, 1045-1051.	1.7	7
556	Improving the global care of familial hypercholesterolaemia: Starting the ball rolling. Atherosclerosis, 2018, 277, 230-233.	0.8	7
557	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 286, 40-45.	0.8	7
558	Dyslipidaemia in adults with type 1 diabetes"when to treat?. Diabetes/Metabolism Research and Reviews, 2019, 35, e3090.	4.0	7

#	ARTICLE	IF	CITATIONS
559	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. <i>Clinical Genetics</i> , 2020, 97, 257-263.	2.0	7
560	Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158869.	2.4	7
561	Validity and reliability of an adapted questionnaire measuring knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 39.	1.7	7
562	Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 841-852.	2.6	7
563	Effectiveness of proprotein convertase subtilisin/kexin monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic. <i>Clinical Cardiology</i> , 2021, 44, 805-813.	1.8	7
564	Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial. <i>Atherosclerosis</i> , 2021, 334, 57-65.	0.8	7
565	Unravelling lipoprotein metabolism with stable isotopes: tracing the flow. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154887.	3.4	7
566	Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. <i>Clinical Biochemist Reviews</i> , 2004, 25, 31-48.	3.3	7
567	Lecithin cholesterol acyltransferase deficiency presenting with acute pancreatitis: effect of infusion of normal plasma on triglyceride-rich lipoproteins. <i>Journal of Internal Medicine</i> , 1995, 238, 137-141.	6.0	6
568	Quantitative coronary cineangiography for the study of atherosclerosis. <i>Medical Engineering and Physics</i> , 1995, 17, 356-365.	1.7	6
569	The implications of the detection of proteinuria and microalbuminuria in insulin and non-insulin dependent diabetes. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 157-161.	0.5	6
570	Reduced forearm reactive hyperaemia in normoalbuminuric subjects with Type 1 diabetes and retinopathy. <i>Diabetic Medicine</i> , 2004, 21, 931-935.	2.3	6
571	The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. <i>Current Opinion in Lipidology</i> , 2008, 19, 592-599.	2.7	6
572	Nutrition and metabolism: nutritional therapy for disordered triglyceride metabolism and nonalcoholic fatty liver disease. <i>Current Opinion in Lipidology</i> , 2010, 21, 545-547.	2.7	6
573	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 987-997.	1.5	6
574	Into the future: diversifying lipid management. <i>Lancet, The</i> , 2012, 380, 1971-1974.	13.7	6
575	Novel Insights Into the Regulation of Postprandial Lipemia by Glucagon-Like Peptides: Significance for Diabetes. <i>Diabetes</i> , 2013, 62, 336-338.	0.6	6
576	Critical review of non-statin treatments for dyslipoproteinemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 359-371.	1.5	6

#	ARTICLE	IF	CITATIONS
577	The hinterland of familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 475-483.	2.7	6
578	Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 363-366.	3.1	6
579	Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 299-312.	2.4	6
580	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. <i>Atherosclerosis</i> , 2018, 277, 470-476.	0.8	6
581	Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1734-1736.	4.4	6
582	The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients. , 2019, 29, 377-385.		6
583	Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?. <i>Clinical Genetics</i> , 2020, 97, 543-555.	2.0	6
584	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. <i>Current Medicinal Chemistry</i> , 2021, 28, 6066-6081.	2.4	6
585	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
586	HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease. <i>Clinical Biochemist Reviews</i> , 2004, 25, 7-18.	3.3	6
587	Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?. <i>European Journal of Clinical Investigation</i> , 2022, , e13766.	3.4	6
588	Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 1297-1312.	0.8	6
589	Effect of Ketones and Glucose on the Estimation of Urinary Creatinine: Implications for Microalbuminuria Screening. <i>Diabetic Medicine</i> , 1990, 7, 263-265.	2.3	5
590	Comparison of intraperitoneal and posterior subcutaneous abdominal adipose tissue compartments as predictors of VLDL apolipoprotein B-100 kinetics in overweight/obese men. <i>Diabetes, Obesity and Metabolism</i> , 2003, 5, 202-206.	4.4	5
591	Dyslipidemia in the metabolic syndrome. <i>Journal of Drug Evaluation</i> , 2004, 2, 3-34.	0.0	5
592	Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?. <i>Clinical Endocrinology</i> , 2005, 63, 650-656.	2.4	5
593	Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. <i>Clinical Endocrinology</i> , 2006, 65, 752-759.	2.4	5
594	High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies. <i>European Journal of Clinical Investigation</i> , 2006, 36, 626-632.	3.4	5

#	ARTICLE	IF	CITATIONS
595	Genetic determinants of apolipoprotein B-100 kinetics. <i>Current Opinion in Lipidology</i> , 2010, 21, 141-147.	2.7	5
596	Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 349-357.	3.4	5
597	Response to Familial Hypercholesterolemia: An Under-recognized but Significant Concern in Cardiology Practice Foody JM et al. <i>Clin Cardiol</i> . doi: 10.1002/clc.22223.. <i>Clinical Cardiology</i> , 2014, 37, 386-387.	1.8	5
598	Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1278-1279.	1.5	5
599	Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2016, 27, 550-556.	2.7	5
600	Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte. <i>Clinical Science</i> , 2017, 131, 791-797.	4.3	5
601	Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. <i>Journal of Clinical Apheresis</i> , 2021, 36, 48-58.	1.3	5
602	Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit. <i>Heart Lung and Circulation</i> , 2021, 30, 734-740.	0.4	5
603	Evolving worldwide approaches to lipid management and implications for Australian general practice. <i>Australian Journal of General Practice</i> , 2021, 50, 297-304.	0.8	5
604	Ankylosing Spondylitis and Risk of Cardiac Arrhythmia and Conduction Disorders: A Systematic Review and Meta-analysis. <i>Current Cardiology Reviews</i> , 2021, 17, e150521193326.	1.5	5
605	Predictors of ceasing or reducing statin medication following a large increase in the consumer copayment for medications: a retrospective observational study. <i>Public Health Research and Practice</i> , 2020, 30, .	1.5	5
606	The Inherited Hypercholesterolemias. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 511-537.	3.2	5
607	Short-term effects of mepacrine on serum lipids, lipoproteins, and apolipoproteins in patients with non-insulin-dependent diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 131-134.	3.4	4
608	Familial Hypercholesterolaemia Regression Study and its implications. <i>Lancet, The</i> , 1995, 345, 807-808.	13.7	4
609	Coronary disease, dyslipidaemia and clinical trials in type 2 diabetes mellitus. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2000, 17, 54-59.	0.2	4
610	Genes and diabetic nephropathy: what have we learnt so far?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2000, 17, 84-90.	0.2	4
611	C-reactive protein: a new cardiovascular risk factor?. <i>Medical Journal of Australia</i> , 2000, 173, 117-118.	1.7	4
612	Normocholesterolaemic dyslipidaemia: is there a role for fibrates?. <i>Medical Journal of Australia</i> , 2001, 174, 66-67.	1.7	4

#	ARTICLE	IF	CITATIONS
613	Postischemic Microcirculatory Blood Flow Correlates Negatively and Independently With Plasma C-Reactive Protein in Longstanding Type 1 Diabetes. <i>Diabetes Care</i> , 2002, 25, 802-803.	8.6	4
614	Polymorphism in postinsulin receptor signaling pathway is not associated with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2008, 90, 2298-2303.	1.0	4
615	Family history: the neglected risk factor in disease prevention. <i>Medical Journal of Australia</i> , 2010, 193, 429-430.	1.7	4
616	Screening for lipid disorders. <i>Pathology</i> , 2012, 44, 115-121.	0.6	4
617	ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1398-1406.	3.6	4
618	Dyslipidemia in Obesity. , 2016, , 525-540.		4
619	Detecting familial hypercholesterolemia: The Jack and the Beanstalk principle. <i>Journal of Clinical Lipidology</i> , 2017, 11, 575-578.	1.5	4
620	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. <i>Atherosclerosis</i> , 2017, 263, 112-118.	0.8	4
621	The evolving model of care for familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1729-1732.	1.8	4
622	Acute Impact of Different Exercise Modalities on Arterial and Platelet Function. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 785-791.	0.4	4
623	Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. <i>Diabetes Research and Clinical Practice</i> , 2018, 141, 156-167.	2.8	4
624	Residual vascular risk in diabetes â€œ Will the SPPARM alpha concept hold the key?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2723-2725.	3.6	4
625	To test, or not to test: that is the question for the future of lipoprotein(a). <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 241-250.	1.5	4
626	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. <i>Internal Medicine Journal</i> , 2021, 51, 769-779.	0.8	4
627	Negatively-charged Liposome Nanoparticles Can Prevent Dyslipidemia and Atherosclerosis Progression in the Rabbit Model. <i>Current Vascular Pharmacology</i> , 2022, 20, 69-76.	1.7	4
628	Familial lipoprotein lipase (LPL) deficiency: A catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. <i>Human Mutation</i> , 1997, 10, 465-473.	2.5	4
629	Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a). <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 174-180.	2.3	4
630	Comparison of Urinary Albumin, Retinol-Binding Protein and N-Acetyl Î²-Glucosaminidase as Predictors of Progression of Low Level Albuminuria in Diabetes. <i>Annals of Clinical Biochemistry</i> , 1997, 34, 202-204.	1.6	3



#	ARTICLE	IF	CITATIONS
631	NICE Guidance on Familial Hypercholesterolaemia: All Sugar and Spice?. Heart Lung and Circulation, 2009, 18, 181-183.	0.4	3
632	LDL apheresis for familial hypercholesterolemia: value, indications and demand. Clinical Lipidology, 2009, 4, 129-131.	0.4	3
633	A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemann-Pick disease type B presenting to a lipid disorders clinic. Annals of Clinical Biochemistry, 2014, 51, 615-618.	1.6	3
634	Impact of commonly prescribed exercise interventions on platelet activation in physically inactive and overweight men. Physiological Reports, 2016, 4, e12951.	1.7	3
635	Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?. Current Hypertension Reports, 2017, 19, 30.	3.5	3
636	The value of counting WHO-defined cardiovascular risk factors for death and disability in a national sample of adults with psychosis. Schizophrenia Research, 2017, 182, 13-18.	2.0	3
637	Squaring up the health economics of PCSK9 monoclonal antibodies – down under™. International Journal of Cardiology, 2018, 267, 193-194.	1.7	3
638	Atherogenic Dyslipoproteinemia and Management of ASCVD. Journal of the American College of Cardiology, 2020, 75, 2136-2139.	2.8	3
639	Metabolism of lipoprotein(a). Current Opinion in Lipidology, 2020, 31, 163-165.	2.7	3
640	Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. Pathology, 2020, 52, 447-452.	0.6	3
641	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. American Journal of Preventive Cardiology, 2021, 6, 100151.	3.0	3
642	Angiotensin-like protein 3 inhibitors and contemporary unmet needs in lipid management. Current Opinion in Lipidology, 2021, 32, 210-212.	2.7	3
643	Implications of new clinical practice guidance on familial hypercholesterolaemia for Australian general practitioners. Australian Journal of General Practice, 2021, 50, 616-621.	0.8	3
644	Dyslipidemia in the metabolic syndrome. Journal of Drug Evaluation, 2004, 2, 3-34.	0.0	3
645	Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies. Current Opinion in Lipidology, 2021, 32, 378-385.	2.7	3
646	Recent advances in the investigation of lipoprotein metabolism using tracer methodology. Clinical Laboratory, 2006, 52, 353-61.	0.5	3
647	Setting the standards for diabetes care: Microalbuminuria. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1992, 9, 84-86.	0.2	2
648	No Association Between Serum Platelet-derived Growth Factor, Platelet Size, and Regression of Angiographically-defined Coronary Artery Disease. Platelets, 1994, 5, 135-138.	2.3	2

#	ARTICLE	IF	CITATIONS
649	Metabolic and cardiovascular risk in the polycystic ovary syndrome. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2005, 22, 261-265.	0.2	2
650	Chylomicrons in disease: A renaissance in lipidology. Atherosclerosis Supplements, 2008, 9, 1-2.	1.2	2
651	Estimating LDL ApoB: Infomania or Clinical Advance?. Clinical Chemistry, 2008, 54, 782-784.	3.2	2
652	Hypertriglyceridaemia in statin-treated type 2 diabetic patients. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2011, 28, 257-260.	0.2	2
653	Familial hypercholesterolaemia in Australia: new insights and developments. Medical Journal of Australia, 2013, 198, 72-73.	1.7	2
654	A framework for bridging the gap in the care of familial hypercholesterolaemia in the community. International Journal of Evidence-Based Healthcare, 2014, 12, 244-254.	0.5	2
655	Screening for familial hypercholesterolemia: primary care applications. Clinical Lipidology, 2015, 10, 295-298.	0.4	2
656	Diabetes, statins and FH. International Journal of Cardiology, 2016, 203, 575.	1.7	2
657	The role of arterial elasticity and cardiovascular peripheral resistance as clinically relevant indices of health status in people with psychosis. Schizophrenia Research, 2017, 184, 88-95.	2.0	2
658	Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical Research. Frontiers in Public Health, 2017, 5, 224.	2.7	2
659	Relationship between pulse pressure and inflammation with left ventricular diastolic dysfunction in chronic kidney disease patients. Internal Medicine Journal, 2019, 49, 240-247.	0.8	2
660	Homozygous familial hypercholesterolaemia in childhood – The first case report in Southeast Europe. Atherosclerosis Supplements, 2019, 40, 122-124.	1.2	2
661	Vulnerabilities in diabetic eye screening for children and young people in England. Pediatric Diabetes, 2019, 20, 932-940.	2.9	2
662	A window into the heart of familial hypercholesterolaemia in the community. Lancet Public Health, The, 2019, 4, e216-e217.	10.0	2
663	PCSK9 in HIV infection: New opportunity or red herring?. Atherosclerosis, 2019, 284, 216-217.	0.8	2
664	Awareness of familial hypercholesterolaemia in Australian primary care: A qualitative descriptive study. Australian Journal of General Practice, 2021, 50, 634-640.	0.8	2
665	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 104-113.	2.3	2
666	Microplastics, cardiometabolic risk, genetics and Alzheimer's disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 85-86.	2.3	2

#	ARTICLE	IF	CITATIONS
667	A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia. <i>Journal of Clinical Lipidology</i> , 2022, 16, 525-529.	1.5	2
668	Association Between Vitamin D Supplementation and Statin-Associated Muscle Symptoms: A Systematic Review. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 337-351.	2.2	2
669	Serum fructosamine and glycosylated haemoglobin in the monitoring of glycaemic control in insulin-dependent diabetic outpatients. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1989, 6, 159-162.	0.2	1
670	Privatization and Company Restructuring in Eastern Europe. <i>Journal of East-West Business</i> , 1998, 4, 29-46.	0.7	1
671	HDL kinetics, fish oils and diabetes. <i>Atherosclerosis</i> , 2001, 159, 243-244.	0.8	1
672	Diet, obesity and endothelial dysfunction: of rats and men. <i>Clinical Science</i> , 2001, 101, 345-347.	4.3	1
673	Measuring arterial stiffness in diabetic patients. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 25-30.	0.2	1
674	Earlier insulin therapy for type 2 diabetes: striving for cost-effectiveness. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 45-46.	0.2	1
675	Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or hormones for courses?. <i>European Heart Journal</i> , 2004, 25, 716-719.	2.2	1
676	Diabetes and the Kidney. , 2006, , 21-47.		1
677	Differences in plasma PLTP activity assays: constant or random error?. <i>Clinical Endocrinology</i> , 2007, 67, 317-317.	2.4	1
678	Nutrition and metabolism: new insights into lifestyle modifications and pharmacotherapy for managing cardiometabolic risk. <i>Current Opinion in Lipidology</i> , 2008, 19, 617-619.	2.7	1
679	Nutrition and metabolism: new studies of the effects of diets and exercise on lipid and lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2010, 21, 91-92.	2.7	1
680	Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 175-176.	0.4	1
681	The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.. <i>Clinical Endocrinology</i> , 2010, 73, no-no.	2.4	1
682	Progress in understanding postprandial dyslipidaemia: Second International Symposium on the Role of Chylomicrons in Disease I. <i>Atherosclerosis Supplements</i> , 2010, 11, 1-2.	1.2	1
683	Dyslipidemia in Obesity. , 2015, , 1-18.		1
684	Statins and Mipomersen: Mechanisms of Action and Patient Tolerability. , 2015, , 73-86.		1

#	ARTICLE	IF	CITATIONS
685	Under-Recognised and Underestimated: The Cardiovascular Health Burden of Familial Hypercholesterolaemia. <i>Heart Lung and Circulation</i> , 2016, 25, 1045-1047.	0.4	1
686	Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia. <i>BMJ Open</i> , 2017, 7, e013691.	1.9	1
687	PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?. <i>Journal of Clinical Lipidology</i> , 2018, 12, 844-848.	1.5	1
688	Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH. <i>Atherosclerosis</i> , 2019, 281, 145-147.	0.8	1
689	Increased risk of 2-year death in patients who discontinued their use of statins. <i>Journal of Health Services Research and Policy</i> , 2021, 26, 95-105.	1.7	1
690	Evaluation of Transthoracic Echocardiography in the Assessment of Atherosclerosis of the Left Main Coronary Artery: Comparison with Optical Frequency Domain Imaging (a Pilot Study). <i>Journal of Clinical Medicine</i> , 2021, 10, 256.	2.4	1
691	A compass for navigating the perils of hypertriglyceridaemia. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 248-249.	11.4	1
692	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. <i>Open Heart</i> , 2021, 8, e001710.	2.3	1
693	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 18708.	3.3	1
694	Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1780-1785.	3.0	1
695	Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations. <i>Current Opinion in Lipidology</i> , 2021, Publish Ahead of Print, 355-362.	2.7	1
696	Familial hypercholesterolaemia and cascade testing in general practice: Lessons from COVID-19. <i>Australian Journal of General Practice</i> , 2020, 49, 859-860.	0.8	1
697	Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, , .	2.0	1
698	Predicting resilience in heterozygous familial hypercholesterolaemia: a cohort study of octogenarian patients. <i>Journal of Clinical Lipidology</i> , 2022, , .	1.5	1
699	The skin in diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1986, 3, 196-199.	0.2	0
700	Quality assessment of visual test strips for home blood glucose monitoring. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1988, 5, 33-35.	0.2	0
701	Serum fructosamine and HbA1. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1989, 6, 285-285.	0.2	0
702	Decision support for the management of lipid disorders using Causal Probabilistic Networks: A development strategy. , 1992, , .		0

#	ARTICLE	IF	CITATIONS
703	Reply to PM Kris-Etherton et al. American Journal of Clinical Nutrition, 1997, 65, 1090.	4.7	0
704	Endothelial dysfunction in Type 1 diabetes mellitus: methodological considerations. Diabetic Medicine, 2000, 17, 687-688.	2.3	0
705	Cardiovascular disease towards 2000: activities of the West Australian Heart Research Institute. Australian and New Zealand Journal of Medicine, 2000, 30, 236-240.	0.5	0
706	Normocholesterolaemic dyslipidaemia: is there a role for fibrates?. Medical Journal of Australia, 2001, 174, 611-611.	1.7	0
707	Diet, obesity and endothelial dysfunction: of rats and men. Clinical Science, 2001, 101, 345.	4.3	0
708	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 183, 222-223.	1.7	0
709	New therapies for familial hypercholesterolemia. Expert Opinion on Therapeutic Patents, 2006, 16, 349-361.	5.0	0
710	Revisiting the metabolic syndrome. Medical Journal of Australia, 2007, 187, 61-61.	1.7	0
711	A national diabetic ketoacidosis protocol: catches for the unwary?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 230-230.	0.2	0
712	More than meets the eye: the ACCORD trial and use of statin+fibrate combination in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 326-328.	0.2	0
713	On Reducing Cardiovascular Disease to a Rarity: Clinical Strategies and their Cost-Effectiveness. Heart Lung and Circulation, 2010, 19, 225-227.	0.4	0
714	Altered metabolism of apolipoprotein C-III: a contributor in chronic kidney disease?. Clinical Lipidology, 2011, 6, 247-251.	0.4	0
715	HSV-2 and atherosclerosis: Adding to the alphabet soup of coronary risk in HIV infection. Atherosclerosis, 2012, 223, 278-279.	0.8	0
716	PANACEA or much a do about nothing: Effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndrome. Atherosclerosis, 2013, 227, 32-34.	0.8	0
717	Through the ophthalmoscope: New insight into the risk of cardiovascular disease in sleep disordered breathing?. Atherosclerosis, 2013, 226, 40-42.	0.8	0
718	More data needed on curcuminoids in hypertriglyceridaemia. Nature Reviews Cardiology, 2014, 11, 123-123.	13.7	0
719	Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy. Contemporary Diabetes, 2014, , 239-278.	0.0	0
720	Sorting the Wheat from the Chaff in Familial Hypercholesterolemia. Clinical Chemistry, 2015, 61, 6-8.	3.2	0

#	ARTICLE	IF	CITATIONS
721	Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes. Heart Lung and Circulation, 2016, 25, 1051-1054.	0.4	0
722	Author reply. Internal Medicine Journal, 2016, 46, 863-863.	0.8	0
723	The shape of things to come in lipid management: a feast of reason. Current Opinion in Lipidology, 2017, 28, 449-451.	2.7	0
724	Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". Circulation, 2017, 136, 120-121.	1.6	0
725	Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2018, 29, 433-435.	2.7	0
726	A web-based registry for rare genetic lipid disorders. Pathology, 2019, 51, S108.	0.6	0
727	What's new on therapies for elevated lipoprotein(a). Expert Review of Clinical Pharmacology, 2019, 12, 495-499.	3.1	0
728	Editorial. Current Opinion in Lipidology, 2019, 30, 417-418.	2.7	0
729	Familial Hypercholesterolaemia Registry in the MENA Region. Current Vascular Pharmacology, 2019, 18, 65-67.	1.7	0
730	The lipid profile in children prior to isotretinoin therapy: an opportunity to detect familial hypercholesterolaemia. Pathology, 2021, 53, 288-290.	0.6	0
731	Under-Reporting of Family History of Premature Coronary Artery Disease in Patients Discharged From Coronary Care: Implications for the Detection of Familial Hypercholesterolaemia. Heart Lung and Circulation, 2021, 30, e48-e49.	0.4	0
732	Editorial: Dyslipidaemia and cardiometabolic health: springboard for an emerging medical specialty?. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 83-84.	2.3	0
733	Therapeutic Regulation of High-Density Lipoprotein Transport in the Metabolic Syndrome. , 2010, , 157-163.		0
734	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. Contemporary Cardiology, 2021, , 615-636.	0.1	0
735	Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities. Clinical Chemistry, 2021, 67, 6-8.	3.2	0
736	Hypertriglyceridemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, Publish Ahead of Print, .	2.3	0
737	Editorial: Familial Hypercholesterolaemia Registry in the MENA Region. Current Vascular Pharmacology, 2019, , 1.	1.7	0
738	Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0